Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$1.58 USD
-0.02 (-1.25%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $1.59 +0.01 (0.63%) 7:22 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LYEL 1.58 -0.02(-1.25%)
Will LYEL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LYEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYEL
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
LYEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Other News for LYEL
What You Missed On Wall Street This Morning
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls
Lyell Immunopharma price target lowered by $3 at BofA, here's why
Hold Rating on Lyell Immunopharma Amid Safety Concerns and Efficacy Doubts for LYL797 Treatment
Lyell Immunopharma just downgraded at H.C. Wainwright, here's why